Frequently Asked Questions (FAQs)
Frequently Asked Questions (FAQs)
What support services does Alnylam Assist™ provide?
Alnylam Assist™ provides patients with product support services, including:
*Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue any program at any time.
Where can I find more materials about ONPATTRO and Alnylam Assist™?
Support and educational materials about ONPATTRO and Alnylam Assist™ can be found on this site.
Who makes up the Alnylam Assist™ team?
Case Managers are experienced in helping individuals get started on treatment and providing ongoing support. They will tailor their method of communication based on what works best for the individual.
Field Reimbursement Directors (FRDs) provide education about coverage, coding, and reimbursement for ONPATTRO. FRDs are knowledgeable about ONPATTRO billing and coding requirements.
Patient Education Liaisons (PELs) have backgrounds in nursing, and are experienced in educating individuals and their families about matters related to hereditary ATTR (hATTR) amyloidosis. PELs can help patients in a variety of ways, including providing disease and product education, connecting patients to additional resources, and answering questions about treatment with ONPATTRO.
What is
Alnylam Assist™?
Alnylam Assist™ includes Case Managers, Patient Education Liaisons, and Field Reimbursement Directors who provide support to patients prescribed Alnylam therapies. This support includes: verification of insurance benefits, coverage and reimbursement education, financial assistance support for eligible patients, and disease and product education. Each member of our team is assigned to specific geographic regions to work with patients, their caregivers, healthcare providers, and insurance companies to support patients throughout treatment on
ONPATTRO® (patisiran).
How do I enroll my patient in the Alnylam Assist™ program?
There are three ways to enroll your patients: